Get the Stockscreener App
1.30
0.78%
0.01
Hoth Therapeutics Inc stock is traded at $1.30, with a volume of 149.89K.
It is up +0.78% in the last 24 hours and down -1.52% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.29
Open:
$1.29
24h Volume:
149.89K
Relative Volume:
0.14
Market Cap:
$17.24M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.9848
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+1.56%
1M Performance:
-1.52%
6M Performance:
+22.64%
1Y Performance:
+79.06%
1-Day Range:
$1.27
$1.32
1-Week Range:
$1.22
$1.32
52-Week Range:
$0.6506
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.30 | 17.10M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Trendlines Suggest Hoth Therapeutics Inc. May Bottom Out SoonWeekly Profit Recap & Daily Volume Surge Trade Alerts - 선데이타임즈
Hoth Therapeutics Holds Annual Shareholder Meeting - MSN
Technical Charts Suggest Momentum Shift in Hoth Therapeutics Inc.Options Play & Accurate Intraday Trading Signals - sundaytimes.kr
Hoth Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Hoth Therapeutics Inc. part of any major indexRocket Fuel Portfolio Alerts - classian.co.kr
Is Hoth Therapeutics Inc. forming a double bottomBest Small Caps with Big Returns - newsyoung.net
Using Bollinger Bands to evaluate Hoth Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
Hoth Therapeutics Inc. stock trend outlook and recovery pathROI Focused Setup Screener With Exit Markers - Newser
What momentum shifts mean for Hoth Therapeutics Inc.Free Community Entry Consensus Trade Ideas - Newser
How to integrate Hoth Therapeutics Inc. into portfolio analysis toolsFree Entry and Exit Strategy Optimizer Tool - Newser
Hoth Therapeutics Inc. Sees Relief Buying After Extended DropMarket Entry and Exit Point Tips From Traders - metal.it
Why Hoth Therapeutics Inc. stock attracts strong analyst attentionDaily Technical Forecast for Quick Gains - Newser
Relative strength of Hoth Therapeutics Inc. in sector analysisFree Daily Chart Pattern Stock Forecast - Newser
Reversal indicators forming on Hoth Therapeutics Inc. stockDaily Pick Forecast with Entry Zones - Newser
Hoth Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
When is Hoth Therapeutics Inc. stock expected to show significant growthBreakthrough stock performance - Jammu Links News
How strong is Hoth Therapeutics Inc. company’s balance sheetOverwhelming profit margins - Jammu Links News
Is Hoth Therapeutics Inc. a good long term investmentStay informed with expert market forecasts - Jammu Links News
What institutional investors are buying Hoth Therapeutics Inc. stockInvest smarter with comprehensive market analysis - Jammu Links News
Hoth Therapeutics Inc. Stock Analysis and ForecastBuild wealth steadily with proven methods - Jammu Links News
Does Hoth Therapeutics Inc. stock perform well during market downturnsPhenomenal wealth increase - Jammu Links News
What catalysts could drive Hoth Therapeutics Inc. stock higher in 2025Breakthrough stock performance - Jammu Links News
What is the risk reward ratio of investing in Hoth Therapeutics Inc. stockBuild wealth faster with professional insights - Jammu Links News
Why is Hoth Therapeutics Inc. stock attracting strong analyst attentionInvest smarter with actionable market insights - Jammu Links News
How many analysts rate Hoth Therapeutics Inc. as a “Buy”Earnings Report Growth Plan For Smart Trading - Jammu Links News
Hoth Therapeutics (HOTH) Expected to Announce Quarterly Earnings on Friday - Defense World
Hoth Therapeutics Regains Nasdaq ComplianceClears Key Listing Hurdle, Reaffirms Path Toward Growth - 富途牛牛
What are the latest earnings results for Hoth Therapeutics Inc.Wealth Building Picks That Work - Jammu Links News
What makes Hoth Therapeutics Inc. stock price move sharplyBest Dividend Data Feed To Watch Now - Jammu Links News
Is a relief rally coming for Hoth Therapeutics Inc. holdersWeekly Return Plan for Conservative Traders - Newser
Hoth Therapeutics Engages ICON to Expand Clinical Trial for HT-001 - Contract Pharma
Hoth Therapeutics shares fall 2.31% premarket after announcing phase II clinical trial expansion in Europe. - AInvest
Hoth Therapeutics Inc. Flashes Rebound Signal in Oversold ConditionInvestment Strategy Designed for Capital Protection - metal.it
Hoth Therapeutics to expand phase II trial of HT-001 to EU countries - Investing.com
Cancer Treatment Breakthrough: Hoth Therapeutics Takes Phase II Trial Global with Major EU Expansion - Stock Titan
Hoth Therapeutics Announces Engagement With ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe - 富途牛牛
What is the dividend policy of Hoth Therapeutics Inc. stockDaily Trading Forecasts From AI Tools - Jammu Links News
Published on: 2025-07-28 20:31:38 - metal.it
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):